Objective-To determine the use of new drugs in one United Kingdom region.
Introduction
Few studies of the pattems of prescribing of new drugs in general practice have been published, because regional data are unavailable to most researchers and because most research is focused on specific therapeutic groups or problems. National prescription pricing databases and pharmaceutical sales databases have occasionally been used for studies of drug use," but we found no studies of the market penetration of new drugs.
Every few years, the drug industry produces important new drugs that are quantitatively and qualitatively different from their predecessors. Two examples are the angiotensin converting enzyme inhibitors and the H2 receptor antagonists. These drugs were quickly accepted by the medical profession because they proved effective, safe, and relatively free from adverse reactions and side effects.
The drug industry also occasionally produces molecular variants of existing drugs-for example, the new, potent broad spectrum oral antibiotics ciprofloxacin and cefuroxime. These antibiotics have a good safety record, are easy to administer, and have side effects similar to those of all broad spectrum antibiotics.
Although these three classes of drugs improve treatment for selected patients, they are more expensive than previous drugs whose benefits are scientifically proved. They should therefore be prescribed only when specifically indicated. The drug industry has heavily promoted these products. We conducted a study to quantify market penetration of these classes of drugs.
Methods
Since 1976 microfiche records ofgeneral practitioner prescribing in Northern Ireland have been kept monthly by the Central Services Agency, Belfast, for every drug dispensed. These records comprise the number of prescriptions issued, the quantity of medicine (numbers of tablets and capsules, volume of liquid) and the mass of drug per item or per 5 ml liquid.
As there are few private practices in Northern Ireland, these data probably account for over 99% of the community dispensing of these drugs. The population ofNorthern Ireland is about 1 600 000.
From these records we calculated the total mass dispensed per month for each drug. This was converted into number of defined daily doses per month by using the classification of the World Health Organisation Collaborating Centre for Drug Statistics Methodology (table I) . ' We studied prescribing data for 1988-91 for angiotensin converting enzyme inhibitors and the antibiotics. Because cimetidine and ranitidine were already well established treatments by 1988, we extended the survey back to 1986, when the market share of ranitidine was approaching that of cimetidine.
Results
The figure shows the defined daily doses per month for the angiotensin converting enzyme inhibitors. ( BMJ VOLUME 307 prescribed in December 1988, increasing to only 5541 in December 1991. By the end of the survey the market share of Carace was only one sixth of that for Zestril. Zestril had achieved 18-4% share of the market whereas Carace had only 2-3%. A similar pattem was seen for quinapril.
H2 RECEPTOR ANTAGONISTS
After its launch in 1978 cimetidine rapidly became established as the drug of choice for managing peptic ulceration, chronic gastritis, and reflux oesophagitis. Experience of its relative safety and freedom from side effects (combined with enthusiastic marketing) encouraged general practitioners to use it when the diagnosis had not been proved, and by 1986, 531 157 defined daily doses per month were being dispensed. A strong competitor of cimetidine, ranitidine, was introduced in 1981 and aggressively marketed. There was widespread media publicity of the drug at the same time as the launch in general practice. Ranitidine is about equally effective in healing peptic lesions and relieving symptoms as cimetidine and has a similar high relapse rate. It costs considerably more and need be prescribed only when cimetidine is contraindicated (a small proportion of patients). This information was given to all general practitioners in Northem Ireland from 1985 onwards during visits from the prescribing liaison doctor. It was then reinforced in 1987 and 1988 in a "best buys list" campaign, in which doctors were asked to consider cost effectiveness. Despite that, 
Discussion
We found that prescription of the three classes of drug increased rapidly over the four years studied. Prescribing was measured in defined daily doses.5
Doses of all drugs vary according to the age of the patient, the severity of the condition, and sometimes the idiosyncrasy of the doctor. The World Health Organisation's defined daily dose does not discriminate between any of these factors nor between duration of treatment, which is possibly even more variable. Nevertheless, it is one of the few tools available for surveying prescription pricing data to determine trends of drug use.
The drug industry has a duty to its shareholders to market the products of scientific research as effectively as possible by all legitimate means, including widespread advertising campaigns, representatives' visits, and heavy promotional activity directed at opinion formers, particularly hospital specialists. Equally, practising doctors, their collegiate bodies, and health service administrators should ensure that promotion of new products does not lead to inappropriate use. In particular, new drugs should not be allowed to replace equally effective, safe, and tolerable established treatment without good cause. There are two main reasons for this. Firstly, the safety of new products remains suspect until sufficient clinical experience is available. Secondly, new treatments are almost always expensive, sometimes much more expensive than existing treatments.
ANGIOTENSIN CONVERTING ENZYME INHIBITORS
An excellent example is the angiotensin converting enzyme inhibitors. There are only two absolute indications for the use of these drugs-with other drugs in managing heart failure and for hypertension uncontrolled by other drugs or drug combinations. They are, however, being promoted and used for all grades of hypertension, including mild hypertension. In such cases a low dose thiazide diuretic combined, if necessary, with a selective i blocker has been proved to be effective, safe, and well tolerated-long term studies have shown a large decrease in cerebrovascular morbidity and mortality, especially in elderly people, and a smaller decrease in coronary morbidity and mortality.67 No such benefits have yet been proved for the angiotensin converting enzyme inhibitors, however likely it is that they will be seen in future. Since these drugs cost up to 30 times more than the cheapest low dose thiazide diuretic, unnecessary prescribing will waste scarce NHS resources. The aging population and a redefinition of diagnostic criteria has caused a real increase of perhaps a fifth in the rate of diagnosis of heart failure. But it is unlikely that the amount of heart failure and refractory hypertension has more than doubled in the past four years, as has prescribing of angiotensin converting enzyme inhibitors.
ANTIBIOTICS
In the case of the two antibiotics studied the companies concemed have been marketing their products for routine treatment of upper and lower respiratory tract, urinary tract, and other infections in general practice. There is little justification for using these drugs for routine treatment, and there may be specific drawbacks to their indiscriminate use. The antipneumococcal activity of ciprofloxacin in vivo has been disappointing,89 and cefuroxime has been commonly associated with gastrointestinal upset." The extra cost of these drugs is another important factor, but perhaps the most serious consequence is the inevitable development of widespread bacterial resistance and an increasing incidence of side effects to these drugs. They may ultimately become ineffective for managing life threatening illness. Doctors and their microbiological advisers are responsible for regulation of prescribing of such drugs, not the drug industry.
Laboratories come under pressure from drug industry representatives to include new products in their battery of antibiotics tested, often under the guise of a study. They may also be pressurised by general practitioners who start to prescribe a new drug and wish to have it screened. But most antibiotics are given presumptively in general practice (without any intention of determining which antibiotics the bacteria are sensitive to), and lack of data on sensitivity does not seem to inhibit prescribing. We found that the four area laboratories differed greatly in their policy on reporting sensitivity to cefuroxime and ciprofloxacin in urine and sputum cultures sent by general practitioners. But increases in prescribing of these antibiotics were similar in the four areas. The area with no consultant microbiological advice had the highest drug use index.
H2 RECEPTOR ANTAGONISTS
One of us (HMcG) has visited general practices throughout Northern Ireland since 1986 to audit prescribing. During these visits he advised general practitioners not to use H2 receptor antagonists except where there is proved disease. This was both because of the risks of camouflaging serious illness, which might have been found by appropriate pretreatment investigations and because of the enormous difference in cost between H2 receptor antagonists and simple antacids. Doctors have (almost always) defended their use of H2 receptor antagonists on the basis of either symptoms alone or in conjunction with minimal physical signs because "there is little risk in using these drugs and investigations are expensive and often difficult to organise." But the drugs are associated with high rates of recurrence of peptic ulceration (80% within a year) and chronic gastritis after healing. This results in patients taking three or four courses a year or long term maintenance. The well tried alternative, a six to eight week course of bismuth chelate, is cheaper, heals 75% of benign ulcers, and has a relapse rate of only 30% at one year." 12 In view of these facts, doctors ought to consider why prescribing of H2 receptor antagonists is increasing.
Our results show that the first drug on the market usually continues to be the market leader. The second drug also seems to flourish, with a smaller market share. The differential between the first and second seems to persist for at least four years. Competing drugs generally take their market share from the market leaders rather than from smaller competitors. CONCLUSION We have shown a simple technique for revealing pattems of prescribing in a region or family health services authority. The data do not relate to individual prescribers and are thus not threatening. They do, however, highlight doctors' joint responsibility to take appropriate action when effective and legal marketing is causing unjustifiable changes in medical practice. Studies such as ours can provide evidence of these changes. We suggest that a drug use index should be monitored for all new drugs.
